The studies behind what you read here, newest first, each with a date and a source. No hype, no cherry-picking.
What they found. The FDA approved the brand-name form of tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity. It was the first medication approved for the condition.
Why it matters. Before this, the options were devices, mouthguards, and surgery. Compounded tirzepatide was not part of this approval.
What they found. In adults with obesity and moderate-to-severe sleep apnea, breathing pauses dropped by about 25 an hour in people not using CPAP and about 29 an hour in people using it, versus about 5 on placebo. People on tirzepatide lost roughly 18 to 20% of their body weight, and their blood pressure came down too.
Why it matters. It's the strongest evidence yet that treating weight with medication can ease sleep apnea. These trials studied the brand-name form. Compounded tirzepatide wasn't tested.
What they found. Researchers took MRI scans of the airway in 67 adults with obesity and sleep apnea before and after weight loss. People lost close to 10% of their body weight over six months, and their sleep apnea scores improved by about 31%. Less fat in the tongue was the strongest link between the weight lost and the improvement.
Why it matters. It helps explain why losing weight can ease sleep apnea: some of the change happens inside the airway itself.
What they found. Researchers estimated that about 936 million adults aged 30 to 69 worldwide have obstructive sleep apnea, and about 425 million of them have moderate-to-severe sleep apnea.
Why it matters. Sleep apnea is one of the most common health conditions in the world, and most people who have it have never been tested.
What they found. Adults with type 2 diabetes and sleep apnea in an intensive lifestyle program lost about 11 kg (24 lb) in the first year. They had about 10 fewer breathing pauses an hour than the comparison group at one year, and still about 8 fewer at four years, even after regaining some weight. About 1 in 5 were in remission at four years, versus fewer than 1 in 25 in the comparison group.
Why it matters. Weight loss can keep helping the airway for years, even when some of the weight comes back.
What they found. Across the studies reviewed, 46 to 83% of people prescribed CPAP used it less than four hours a night, the usual cutoff for regular use.
Why it matters. CPAP works when it's worn. That's why treatments that work alongside it matter.
What they found. In 589 women in the Wisconsin Sleep Cohort, postmenopausal women had about 2.6 times the odds of sleep-disordered breathing compared with premenopausal women, after accounting for age and body size.
Why it matters. It's one reason sleep apnea in women is easy to miss: the signs get blamed on menopause itself.
What they found. A 10% weight gain was linked to about 32% more breathing pauses an hour, and a 10% weight loss to about 26% fewer.
Why it matters. Even moderate changes in weight can move sleep apnea in either direction.
Last reviewed November 2026. We add new studies as they're published.
What happens to sleep apnea if someone stops the medication? Longer follow-up is still needed.
The big tirzepatide trials ran for one year. Longer-term results are still coming in.
The trials studied adults with obesity. Less is known about people with lower body weight.
Compounded tirzepatide wasn't tested in these trials. It's prepared by licensed pharmacies and isn't FDA-approved.
Compare sleep apnea treatments, old and new.